The number of new graduates hired for sales rep roles increased in FY2025 after declining for five consecutive years, a…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Plavix Tops Japan Ethical Drug Ranking, Sales Leap 14%: IMS
February 21, 2014
-
BUSINESS MTPC, Daiichi Sankyo Aim to Boost Sales of Struggling Tenelia
February 20, 2014
-
REGULATORY Tokyo Prosecutors Raid Novartis Japan Office over Diovan Ads
February 20, 2014
-
REGULATORY Penalty for Lengthy Drug Price Haggling – Interview 1: “It Can’t Be Helped” Says Idaikyo Exec Koyama
February 19, 2014
-
ACADEMIA Japan Hypertension Society Halts Support for Maker-Linked Seminars, but Gives Leeway for Luncheons
February 18, 2014
-
BUSINESS Blopress AGs Approved, Yet Blurry Prospect for Their June Listing
February 17, 2014
-
REGULATORY 34 Firms Win Approval for Diovan Generics, 31 for Preminent Generics towards June Listing
February 17, 2014
-
BUSINESS Nichi-Iko on Tap to Enter US Market, Remicade Biosimilar Debut Eyed around 2018
February 14, 2014
-
ACADEMIA University of Tokyo Hospital Allegedly Gave Patient Questionnaire Results on SIGN Trial to Novartis without Consent
February 13, 2014
-
REGULATORY Chuikyo Submits Recommendations for FY2014 Revision; Hospitals, Pharmacies with Low Settlement Rates to Face Fee Cuts of Up to 26％
February 12, 2014
-
ORGANIZATION Prof. Tsuchiya Slams Kowa’s Livalo Trademark Suit
February 10, 2014
-
ACADEMIA University of Tokyo Besieged with Medical, Pharma Research Woes, School’s Credibility at Stake
February 7, 2014
-
BUSINESS Kyorin Pushes Easy to Use Inhaler Flutiform, Aims for Higher Market Penetration
February 6, 2014
-
REGULATORY PMDA’s Next 5-Year Plan to Embrace New Generic Unit, Benchmarks for Review Time
February 5, 2014
-
BUSINESS Drug Wholesalers Laud Medical Fee Cuts to Fix Lengthy Haggling, Pharmacy Chains Vexed by Rule
February 4, 2014
-
BUSINESS Teijin Picks Another Pharma Maven for President
February 3, 2014
-
BUSINESS Sanofi Demands Payment of $416 Million from Novartis over Dissolved Equa Deal
January 31, 2014
-
BUSINESS Novartis Suspected of Drafting Letter of Consent for “Sign” Trial
January 30, 2014
-
BUSINESS Shionogi Influenza Campaign Causes Stir among Healthcare Professionals
January 29, 2014
-
ACADEMIA JCS’s 2013 Guidelines for Treatment of AF Recommend Dabigatran and Apixaban in Moderate-Risk Patients
January 29, 2014
ページ
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…